Atrium Therapeutics Reports Q2 2026 Results, Advances Drug Development
Atrium Therapeutics reported its second quarter 2026 financial results. The company achieved IND clearance for ATR 1072 and launched the Corventis Phase 1/2 trial for PRKAG2 syndrome.
Atrium Therapeutics, Inc. (Nasdaq: RNA) announced its financial results for the second quarter of 2026. The company reported receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its drug candidate ATR 1072. Concurrently, Atrium Therapeutics initiated the Phase 1/2 clinical trial for Corventis, targeting the rare PRKAG2 syndrome.
Furthermore, Atrium Therapeutics achieved its second milestone payment under a global cardiovascular collaboration agreement with Bristol Myers Squibb. This collaboration is structured to include multiple milestone payments and royalties as development progresses.
The company's reported revenue and net loss for the second quarter were in line with expectations. Specific financial figures are slated for release during an upcoming investor call.
The advancement of ATR 1072 and the Corventis trial are expected to be key drivers for the company's future outlook, particularly within the rare cardiovascular disease market.